Impact of antiretroviral drugs on PD‑L1 expression and copy number gains with clinical outcomes in HIV‑positive and ‑negative locally advanced cervical cancers

Loharamtaweethong,Kongsak; Vinyuvat,Songkhun; Thammasiri,Jidapa; Chitpakdee,Sakchai; Supakatitham,Chalermpak; Puripat,Napaporn

doi:10.3892/ol.2019.10963

Impact of antiretroviral drugs on PD‑L1 expression and copy number gains with clinical outcomes in HIV‑positive and ‑negative locally advanced cervical cancers

Authors:
- Kongsak Loharamtaweethong
- Songkhun Vinyuvat
- Jidapa Thammasiri
- Sakchai Chitpakdee
- Chalermpak Supakatitham
- Napaporn Puripat
View Affiliations

Affiliations: Department of Anatomical Pathology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand, Department of Medical Services, Institute of Pathology, Ministry of Public Health, Bangkok 10400, Thailand, Department of Pathology, National Cancer Institute, Bangkok 10400, Thailand, Department of Pathology, Rajavithi Hospital, Bangkok 10400, Thailand
Published online on: October 4, 2019 https://doi.org/10.3892/ol.2019.10963
Pages: 5747-5758
Copyright: © Loharamtaweethong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer has become a leading cause of death in both HIV‑infected and uninfected women. Previous studies have revealed that antiretroviral therapy (ART) possesses anti‑human papillomavirus (HPV) and antitumour properties, potentially serving as an anticancer agent and improving functional immunity in HIV‑positive individuals. However, to the best of our knowledge, no studies have examined the association between ART and the clinical outcome of patients with pre‑existing invasive cervical cancer. The current study analysed 48 HIV‑positive and 123 HIV‑negative patients with locally advanced stage IB2‑IVA cervical cancer between December 2008 and December 2016. Tumours were categorized based on programmed cell death‑ligand 1 (PD‑L1) immunoreactivity and copy number alterations in the PD‑L1 gene, as determined by fluorescence in situ hybridization. The results revealed that ART‑treated patients exhibited a lower prevalence of PD‑L1 immunopositivity, PD‑L1 amplification and polysomy compared with patients that did not receive ART and those that were HIV‑negative. Furthermore, ART‑treated patients with PD‑L1 immunonegativity exhibited an improved recurrence‑free survival (RFS) compared with patients that did not receive ART and HIV‑negative individuals with PD‑L1 immunopositivity (P=0.041 vs. P=0.030). Additionally, ART‑exposed patients with PD‑L1 disomy demonstrated improved locoregional recurrence‑free survival (LRR) when compared with HIV‑negative patients with PD‑L1 amplification and polysomy (P=0.039 vs. P=0.007), RFS (P<0.001 vs. P=0.006) and cancer‑specific survival (CSS) (P=0.021 vs. P=0.025). ART‑exposed patients with PD‑L1 disomy also exhibited improved RFS (P<0.001) and CSS (P<0.001) compared with HIV‑negative patients with PD‑L1 amplification. Improved LRRs were demonstrated in ART‑exposed patients with PD‑L1 disomy (P=0.028) compared with non‑HIV patients with polysomy. Following multivariate analysis, International Federation of Gynaecology and Obstetrics stage and PD‑L1 amplification were determined to be predictors of poor a RFS [hazard ratio (HR), 2.43; 95% confidence interval (CI), 1.37‑4.30; P=0.002 vs. HR, 7.03; 95% CI, 2.79‑17.74; P<0.001) and CSS (HR, 11.47; 95% CI, 4.70‑27.99; P<0.001 vs. HR, 4.05; 95% CI, 1.64‑9.98; P=0.002). However, only PD‑L1 polysomy was determined to be a predictor of poor LRR (HR, 2.50; 95% CI, 1.11‑5.63; P=0.027). HIV status was not associated with poor outcomes, as determined using Cox models. The results of the current study indicated that ART may be used for the treatment of cervical cancer in both HIV‑infected and uninfected patients. However, additional research is required to further elucidate these results.

View Figures

View References

1	1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 41:1–19. 1992.
2	Indian Council of Medical Research, . National Cancer Registry ProgrammeNational Printing Press; India: Bangalore: pp. 60–61. 2001
3	Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP and Hsueh S: Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 60:249–257. 2004. View Article : Google Scholar : PubMed/NCBI
4	Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D and Lockett MA: Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of the uterine cervix: Update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 31:703–716. 1995. View Article : Google Scholar : PubMed/NCBI
5	Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005. View Article : Google Scholar : PubMed/NCBI
6	Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007. View Article : Google Scholar : PubMed/NCBI
7	Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and Wasik MA: Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 105:20852–20857. 2008. View Article : Google Scholar : PubMed/NCBI
8	Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4:127ra372012. View Article : Google Scholar : PubMed/NCBI
9	Wu P, Wu D, Li L, Chai Y and Huang J: PD-L1 and survival in solid tumors: A Meta-analysis. PLoS One. 10:e01314032015. View Article : Google Scholar : PubMed/NCBI
10	Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T and Tokura Y: Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 116:1757–1766. 2010. View Article : Google Scholar : PubMed/NCBI
11	Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L and Rimm DL: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar : PubMed/NCBI
12	Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG and Wen WH: B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 8:e760122013. View Article : Google Scholar : PubMed/NCBI
13	Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 116:3268–3277. 2010. View Article : Google Scholar : PubMed/NCBI
14	Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, et al: Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 6:26483–26493. 2015. View Article : Google Scholar : PubMed/NCBI
15	Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
16	Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, et al: Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol. 2:518–522. 2016. View Article : Google Scholar : PubMed/NCBI
17	Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS and Biggar RJ: Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 94:1204–1210. 2002. View Article : Google Scholar : PubMed/NCBI
18	Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A and McKenna TM; Centers for Disease Control Prevention (CDC), : Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep. 57:1–12. 2008.PubMed/NCBI
19	Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ and Engels EA: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 103:753–762. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kelly H, Weiss HA, Benavente Y, de Sanjose S and Mayaud P: Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: A systematic review and meta-analysis. Lancet HIV. 5:e45–e58. 2018. View Article : Google Scholar : PubMed/NCBI
21	Chow WA, Jiang CL and Guan M: Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncol. 10:61–71. 2009. View Article : Google Scholar : PubMed/NCBI
22	Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
23	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
24	Inoue Y, Yoshimura K, Mori K, Kurabe N, Kahyo T, Mori H, Kawase A, Tanahashi M, Ogawa H, Inui N, et al: Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget. 7:32113–32128. 2016. View Article : Google Scholar : PubMed/NCBI
25	Dryden-Peterson S, Bvochora-Nsingo M, Medhin H, Suneja G, Asmelash A, Pusoentsi M, Russell A, Efstathiou J, Chabner B, Lockman S, et al: HIV infection and survival among women with cervical cancer. J Clin Oncol. 34:3749–3757. 2016. View Article : Google Scholar : PubMed/NCBI
26	Batman G, Oliver AW, Zehbe I, Richard C, Hampson L and Hampson IN: Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir Ther. 16:515–525. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xulu KR and Hosie MJ: HAART induces cell death in a cervical cancer cell line, HCS-2: A scanning electron microscopy study. J Microsc Ultrastruct. 5:39–48. 2017. View Article : Google Scholar : PubMed/NCBI
28	Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K and Azuma M: Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 42:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
29	Ritprajak P and Azuma M: Intrinsic and extrinsic control of expression of the immunoregulatory molecule pd-l1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 51:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
30	Tudela EV, Singh MK, Lagman M, Ly J, Patel N and Venketaraman V: Cytokine levels in plasma samples of individual with HIV infection. Austin J Clin Immunol. 1:10032014.
31	De Luca A, Giancola ML, Cingolani A, Ammassari A, Murri R and Antinori A: Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: The effect of protease inhibitor therapy. AIDS Res Hum Retroviruses. 16:835–843. 2000. View Article : Google Scholar : PubMed/NCBI
32	Watanabe D, Uehira T, Yonemoto H, Bando H, Ogawa Y, Yajima K, Taniguchi T, Kasai D, Nishida Y and Shirasaka T: Sustained high levels of serum interferon-gamma during HIV-1 infection: A specific trend different from other cytokines. Viral Immunol. 23:619–625. 2010. View Article : Google Scholar : PubMed/NCBI
33	Piconi S, Trabattoni D, Fusi ML, Milazzo F, Dix LP, Rizzardini G, Colombo F, Bray D and Clerici M: Effect of two different combinations of antiretrovirals (AZT + ddI and AZT + 3TC) on cytokine production and apoptosis in asymptomatic HIV infection. Antiviral Res. 46:171–179. 2000. View Article : Google Scholar : PubMed/NCBI
34	Inoue Y, Matsuura S, Kurabe N, Kahyo T, Mori H, Kawase A, Karayama M, Inui N, Funai K, Shinmura K, et al: Clinicopathological and survival analysis of Japanese patients with resected non-small-cell lung cancer harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA gene amplification. J Thorac Oncol. 10:1590–1600. 2015. View Article : Google Scholar : PubMed/NCBI
35	Boulware DR, Meya DB, Bergemann TL, Williams D, Vlasova-St Louis IA, Rhein J, Staddon J, Kambugu A, Janoff EN and Bohjanen PR: Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa. J Acquir Immune Defic Syndr. 55:428–438. 2010. View Article : Google Scholar : PubMed/NCBI
36	Massanella M, Singhania A, Beliakova-Bethell N, Pier R, Lada SM, White CH, Pérez-Santiago J, Blanco J, Richman DD, Little SJ and Woelk CH: Differential gene expression in HIV-infected individuals following ART. Antiviral Res. 100:420–428. 2013. View Article : Google Scholar : PubMed/NCBI
37	Maggiorella L, Wen B, Frascogna V, Opolon P, Bourhis J and Deutsch E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res. 25:4357–4362. 2005.PubMed/NCBI
38	Ulrike K, Markus H, Thomas H, Ellen H, Barbara S, Rainer F and Distel LV: NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients. Radiother Oncol. 116:323–330. 2015. View Article : Google Scholar : PubMed/NCBI
39	Borcoman E and Le Tourneau C: Pembrolizumab in cervical cancer: Latest evidence and clinical usefulness. Ther Adv Med Oncol. 9:431–439. 2017. View Article : Google Scholar : PubMed/NCBI